Selenium and Breast Cancer Chemoprevention
Abstract
The primary objective of this project was to determine whether selenium supplementation affected candidate markers of breast cancer risk in a cohort of women at elevated risk for breast cancer. The intermediate biomarkers being studied were: indicators of oxidative damage to cellular macromolecules such as DNA and lipid indicators of IGF metabolic status and cellular indicators of breast cancer risk. We conducted a randomized, placebo-controlled double-blind chemoprevention trial with 150 participants (75 subjects per arm) using a placebo tablet or a tablet containing 200 microg high-selenium brewer's yeast per day, given for a duration of one year. The form and dose of selenium that was being used has been reported to reduce cancer incidence and mortality in lung, prostate and colon. Blood and urine were collected at baseline and after 6 and 12 months of intervention. The feasibility of obtaining breast epithelial cells via nipple aspiration at baseline and the end of the intervention was assessed. Plasma selenium and glutathione peroxidase activity were evaluated in addition to pill counts and self report as markers of compliance.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2006
- Accession Number
- ADA467942
Entities
People
- Henry J. Thompson
Organizations
- Colorado State University